The grades of six Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, Elan (NYSE:ELN) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Elan engages in research, development, and commercial activities primarily in the areas of Alzheimers disease, Parkinsons disease, and multiple sclerosis (MS). For more information, get Portfolio Grader’s complete analysis of ELN stock.
This week, Eli Lilly (NYSE:LLY) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.
This week, Merck‘s (NYSE:MRK) ratings are up from a B last week to an A. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The price of MRK is up 2.9% from a month ago. For more information, get Portfolio Grader’s complete analysis of MRK stock.
This week, Pfizer (NYSE:PFE) pushes up from a B to an A rating. Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. PFE shares have increased 6.4% since last month. For more information, get Portfolio Grader’s complete analysis of PFE stock.
This is a strong week for Lannett Co. (AMEX:LCI). The company’s rating climbs to B from the previous week’s C. Lannett manufactures and distributes pharmaceutical products under its own trade name and under generic names. LCI shares are up 5% from last month. For more information, get Portfolio Grader’s complete analysis of LCI stock.
The rating of Acura Pharmaceuticals (NASDAQ:ACUR) moves up this week, rising from a C to a B. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.